[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microrna\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microrna":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,77,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100612960","the-difference-of-microrna-and-circulating-tumor-cells-in-blood-among-cancer-patients-with-immunotherapy-100612960",false,"NCT07260370","The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy","The Difference of microRNA Signature(S) and Circulating Tumor Cells in Blood Among Cancer Patients Before and Afte Immunotherapy","Inclusion Criteria:\n\n1. Aged above 20 years.\n2. A patient diagnosed with cancer with immunotherapy\n3. Competent to give informed consent and agree to join the study.\n\nExclusion Criteria:\n\n1. Aged \\\u003C 20 years.\n2. Refuse to join the study","ALL","20 Years",{"count":19,"type":20},300,"ESTIMATED","3 Months","OBSERVATIONAL","Among the currently important biomarkers, circulating tumor cells and microRNA (miRNA) have received significant attention. The latter, also translated as micro-ribonucleic acid, is a widely present ribonucleic acid (RNA) molecule in eukaryotes, approximately 21 to 23 nucleotides in length, which regulates the expression of other genes. miRNAs originate from RNAs that are transcribed from DNA but cannot be further translated into proteins (classified as non-coding RNA). miRNAs bind to target messenger RNA (mRNA), thereby inhibiting post-transcriptional gene expression, and play important roles in regulating gene expression, the cell cycle, and the timing of biological development.The project will recruit 300 subjects who have been diagnosed with cancer by a physician and for whom the decision has been made to use immunotherapy. Blood samples will be collected before and after treatment (past pathological diagnostic tissues may also be reviewed as required for the study). The study will analyze the differences in the quantity of free microRNAs, the number of circulating tumor cells, and the differences in surface antigen expression in the subjects' blood, as well as the specific surface antigen expression status in the cancer tissues, and perform statistical analysis.",[25,26,27],"microRNA","Circulating Tumor Cells","Immunotherapy",[29,30,27,25,31],"Cancer","Plasma","Circulating Tumor Cell","RECRUITING","2025-11-21",{"date":35,"type":36},"2025-12-03","ACTUAL",{"date":38,"type":36},"2018-05-23",{"date":40,"type":20},"2026-04-30",{"name":42,"class":43},"Chang Gung Memorial Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100557955","trial-to-evaluate-the-clinical-utility-of-non-invasive-endometrial-receptivity-test-ora-in-patients-with-implantation-failure-100557955","NCT06544837","Trial to Evaluate the Clinical Utility of Non-invasive Endometrial Receptivity Test (Ora) in Patients With Implantation Failure","Multi-national, Multi-center, Randomized Controlled Trial to Evaluate the Clinical Utility of Non-invasive Endometrial Receptivity Test (Ora) in Patients With Implantation Failure","Inclusion Criteria:\n\n* Experienced implantation failure with euploid or low-level mosaic (\\\u003C 30%) embryos in the past two years.\n* Female age 28-45 years.\n* Consent to undergo a simulated cycle for non-invasive optimal implantation window testing.\n* Plan to undergo a frozen embryo transfer cycle.\n* Have at least one euploid or low-level mosaic (\\\u003C 30%) frozen blastocyst.\n\nExclusion Criteria:\n\n* Presence of uterine cavity abnormalities that may affect implantation, such as polyps, fibroids ≧4 cm, or hydrosalpinx\n* Presence of systemic diseases that may affect reproductive techniques (e.g., autoimmune diseases)\n* Body mass index (BMI) over 30 kg\u002Fm²","FEMALE","28 Years","45 Years",{"count":56,"type":20},1000,"INTERVENTIONAL",[59],"NA","The adjustment of the timing of embryo transfer based on the endometrial receptivity profile and transferring embryo(s) of good quality with normal chromosomes (diagnosed by Preimplantation Genetic Testing for Aneuploidy, PGT-A) are the two main causes to improve the success of assisted reproduction treatments (ART). Previously, endometrial receptivity analysis was performed on women undergoing IVF treatment through an invasive endometrial tissue biopsy. The aim of this study is to determine the clinical benefits of ORA, a novel non-invasive endometrial receptivity test that determines the optimal time for embryo transfer through a blood draw instead of an invasive endometrial tissue biopsy. It is expected to recruit 1000 couples whose embryos will be analyzed by PGT-A and\u002For who are going to evaluate their endometrium expression profile for endometrial receptivity. The patients will be randomized into two groups, (1) Control group : undergoing PGT-A only; (2) Study group : the undergoing both PGT-A and ORA. ART will be performed based on the results of PGT-A and\u002For ORA. Reproductive success, such as implantation rates (IR), pregnancy rates (PR), ongoing pregnancy rates (OGP) and live birth rates (LBR) will be tracked and compared.\n\nPreliminary results demonstrate that both PGT-A and ORA can contribute to reproductive success, improving implantation rates in patients with implantation failure. Our hypothesis suggests that PGT-A and ORA could improve the performance of ART in infertile patients.",[62,63,25,64,65,66],"IVF","Window of Implantation","Implantation","Non-invasive Testing","Endometrial Receptivity","2025-05-04",{"date":69,"type":36},"2025-05-07",{"date":71,"type":36},"2024-06-22",{"date":73,"type":20},"2027-06-01",{"name":75,"class":76},"Inti Labs","INDUSTRY",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100554337","the-application-of-dna-nanomachines-for-detecting-microrna-in-blood-for-the-diagnosis-of-pancreatic-cancer-diagnosis-of-pancreatic-cancer-100554337","NCT06497777","The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer","The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer.","Inclusion Criteria:\n\n* Pancreatic ductal adenocarcinoma\n* Proven by pathology\n* Patients who have not received anti-cancer therapies\n\nExclusion Criteria:\n\n* Less than 20 years old\n* Unable to provide inform and consent\n* Patients who have active malignancy other than pancreatic adenocarcinoma\n* Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing\n* Life expectancy less than 3 months",true,{"count":86,"type":20},30,"Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis prediction of pancreatic cancer. The current primary method for detecting microRNAs is RT-qPCR, but this process requires repeated temperature cycling, which demands high precision from the equipment. As an alternative, isothermal nucleic acid amplification technology does not require expensive temperature control instruments. Our research team has developed various isothermal nucleic acid amplification strategies for microRNA sensing platforms, applied to biological sample detection. This study combines the circular strand displacement amplification strategy with DNA nanomachines to develop a fluorescence sensing platform that performs dual signal amplification at a constant temperature. It is designed to detect pancreatic cancer-related microRNAs, exploring its role and potential applications in the diagnosis of pancreatic cancer patients.",[89,90],"Pancreas Adenocarcinoma","MicroRNA",[90,89],"2024-07-05",{"date":94,"type":36},"2024-07-12",{"date":96,"type":20},"2024-07-06",{"date":98,"type":20},"2026-06-01",{"name":100,"class":43},"National Taiwan University Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":111,"conditions":112,"keywords":118,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":44},"100430743","coronary-artery-calcification-in-type-2-diabetes-mellitus-uscac-study-100430743","NCT04889053","Coronary Artery Calcification in Type 2 Diabetes Mellitus (USCAC Study)","Prospective Cohort Study of Coronary Artery Calcification in Type 2 Diabetes Mellitus (USCAC Study)","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Type 2 diabetes is diagnosed according to WHO diagnostic criteria\n* Low dose prospectively triggered sequential dual-source CT coronary angiography can be performed at baseline investigation\n* Those subjects are able to understand the purpose and procedure of this study and sign the informed consent voluntarily\n\nExclusion Criteria:\n\n* Those have received coronary artery stenting or coronary artery bypass grafting\n* Those with severe lung (respiratory failure), liver (ALT or AST 3 times normal value or bilirubin increase), renal dysfunction\\[GFR \\\u003C 45ml\u002F(min.1.73m2) or dialysis patients\n* Malignant tumor\n* Mental illness or mental retardation\n* Pregnant or lactating women or those with fertility planning\n* Concomitant diseases (hyperparathyroidism, sarcoidosis, amyloidosis) affecting calcium balance and soft tissue calcification\n* Contraindications of contrast agents\n* Based on the judgment of the researcher, the compliance is poor and the study could not be completed according to the requirements","18 Years",{"count":110,"type":20},1400,"Coronary artery calcification (CAC) is a common complication of type 2 diabetes mellitus(T2DM), which can significantly increase all-cause mortality and the incidence of serious cardiovascular events, and increase the burden of the national economy. The epidemiological characteristics and the clinical progress of CAC are still not clear. Moreover, the pathogenesis of CAC has not yet been fully elucidated, and lack of specific diagnostic indicators. Arterial calcification is an active, reversible, and multifactorial biological process like bone formation. It is generally believed that early detection of calcification lesions and active targeted treatment may be the key to prevention and treatment of vascular calcification. In addition, statins are commonly used in patients with dyslipidemia and can stabilize CAC plaque. However, the timing, dosage and effect of statins are controversial. Moreover, our previous study found that the expression of miR-32 is significantly elevated in patients with CAC, and can promoting vascular calcification. Herein, this study is to conduct a prospective cohort study on T2DM patients with CAC in Hunan province through a multidisciplinary and multi-center cooperation model, the main research objectives include the following three parts: ① To identify the prevalence, incidence, and characteristics of CAC in T2DM patients in Hunan province, and to build a risk assessment model. ② To observe the effects of statins on the occurrence and development of CAC in patients with T2DM, and to provide clinical data for the improvement of medication guidelines; ③To observe the dynamic changes of serum miR-32 in the progression of CAC in patients with T2DM, and to explore its possibility as a serological diagnosis or prognostic bio-maker of CAC. The completion of this research project is expected to bring a new breakthrough in the field of early diagnosis, prognosis evaluation, and intervention treatment of patients with T2DM combined with CAC, and provide an important reference for the formulation of cardiovascular disease prevention and control strategy.",[113,114,115,116,117,25],"Type 2 Diabetes","Vascular Calcification","Coronary Artery Calcification","Strains","Epidemiology",[113,119,117,120],"Vascular calcification","microRNA-32","2021-09-27",{"date":123,"type":36},"2021-09-29",{"date":125,"type":36},"2021-06-01",{"date":127,"type":20},"2030-12-31",{"name":129,"class":43},"University of South China"]